News

Meridian’s proprietary liquid formulation of docetaxel injection for the treatment of multiple form of cancer contains Captisol to eliminate Polysorbate 80. The in-vitro study data from CycloLab submitted to FDA show the pharmacology properties of the new formulation, and similarity to taxotere. FDA accepted the plan for the submission of New Drug Application (NDA).

http://www.prnewswire.com/news-releases/meridian-lab-announces-positive-outcome-from-pre-nda-meeting-with-fda-for-ml141-300210162.html

BACK TO NEWS